智通财经APP讯,玮俊生物科技(00660)公布截至2024年6月30日止年度业绩,收入约3.7亿港元,同比减少52.17%;公司拥有人应占亏损4421.2万港元,同比扩大1.86倍;每股亏损25.8港仙。
公告称,收入下降主要归因于报告期内变性淀粉及其他生化产品的市场需求疲软及消费量下降。此外,作为提升整体营运效率的战略重组的一部分,集团已停止某些表现不佳的产品线。这一决定亦导致收入大幅下降。亏损增加主要由于报告年度内非金融资产减值亏损的确认。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.